75%Confidence
0Views
FDASource
2026-04-04Date
Summary
Harvard Drug Group's packaging defect for Midodrine tablets reveals potential supply chain vulnerabilities in blister packaging operations. This could affect patient medication integrity and lead to increased packaging scrutiny across similar products.
Actionable: Verify the packaging integrity of Midodrine tablets in inventory and monitor for potential shortages.
AI Confidence: 75%
Data Points
firmThe Harvard Drug Group LLC
classificationClass II
statusOngoing
distributionNationwide US.
productMidodrine Hydrochloride Tablets, USP, 5 mg, 50 Tablets (5 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapol
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now